Literature DB >> 12477832

The genome length of human parainfluenza virus type 2 follows the rule of six, and recombinant viruses recovered from non-polyhexameric-length antigenomic cDNAs contain a biased distribution of correcting mutations.

Mario H Skiadopoulos1, Leatrice Vogel, Jeffrey M Riggs, Sonja R Surman, Peter L Collins, Brian R Murphy.   

Abstract

Members of the Paramyxovirinae subfamily of the Paramyxoviridae family of viruses have the unusual requirement that the nucleotide length of the viral genome must be an even multiple of six in order for efficient RNA replication, and hence virus replication, to occur. Human parainfluenza virus type 2 (HPIV2) is the only member of the genus that has been reported to have a genome length that is not an even multiple of six, and it has also been recovered from a full-length antigenomic-sense cDNA that did not conform to the "rule of six." To reexamine the issue of nucleotide length in natural isolates of HPIV2, a complete consensus genomic sequence was determined for three HPIV2 strains: Greer, Vanderbilt/1994 (V94), and Vanderbilt/1998. Each of these strains was found to have a genome length of 15,654 nucleotides (nt), thus conforming in each case to the rule of six. To directly examine the requirement that the genomic length of HPIV2 be an even multiple of six, we constructed six full-length antigenomic HPIV2/V94 cDNAs that deviated from a polyhexameric length by 0 to 5 nt. Recombinant HPIV2s were readily recovered from all of the cDNAs, including those that did not conform to the rule of six. One recombinant HPIV2 isolate was completely sequenced for each of the nonpolyhexameric antigenomic cDNAs. These were found to contain small nucleotide insertions or deletions that conferred polyhexameric length to the recovered genome. Interestingly, almost all of the length corrections occurred within the hemagglutinin-neuraminidase and large polymerase genes or the intervening intergenic region and thus were proximal to the insert that caused the deviation from the rule of six. These results demonstrate, in the context of complete infectious virus, that HPIV2 has a strong and seemingly absolute requirement for a polyhexameric genome.

Entities:  

Mesh:

Year:  2003        PMID: 12477832      PMCID: PMC140631          DOI: 10.1128/jvi.77.1.270-279.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  Influenza A virus RNA polymerase has the ability to stutter at the polyadenylation site of a viral RNA template during RNA replication.

Authors:  H Zheng; H A Lee; P Palese; A García-Sastre
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

2.  Long nucleotide insertions between the HN and L protein coding regions of human parainfluenza virus type 3 yield viruses with temperature-sensitive and attenuation phenotypes.

Authors:  M H Skiadopoulos; S R Surman; A P Durbin; P L Collins; B R Murphy
Journal:  Virology       Date:  2000-06-20       Impact factor: 3.616

3.  Recovery of infectious human parainfluenza type 2 virus from cDNA clones and properties of the defective virus without V-specific cysteine-rich domain.

Authors:  M Kawano; M Kaito; Y Kozuka; H Komada; N Noda; K Nanba; M Tsurudome; M Ito; M Nishio; Y Ito
Journal:  Virology       Date:  2001-05-25       Impact factor: 3.616

Review 4.  Pseudo-templated transcription in prokaryotic and eukaryotic organisms.

Authors:  J P Jacques; D Kolakofsky
Journal:  Genes Dev       Date:  1991-05       Impact factor: 11.361

5.  Exonucleolytic proofreading during replication of repetitive DNA.

Authors:  L C Kroutil; K Register; K Bebenek; T A Kunkel
Journal:  Biochemistry       Date:  1996-01-23       Impact factor: 3.162

6.  Oligo(A) sequences of human respiratory syncytial virus G protein gene: assessment of their genetic stability in frameshift mutants.

Authors:  B García-Barreno; T Delgado; J A Melero
Journal:  J Virol       Date:  1994-09       Impact factor: 5.103

7.  Effect of inserting paramyxovirus simian virus 5 gene junctions at the HN/L gene junction: analysis of accumulation of mRNAs transcribed from rescued viable viruses.

Authors:  B He; R A Lamb
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

8.  Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics.

Authors:  Jason T Newman; Sonja R Surman; Jeffrey M Riggs; Chris T Hansen; Peter L Collins; Brian R Murphy; Mario H Skiadopoulos
Journal:  Virus Genes       Date:  2002       Impact factor: 2.332

9.  Frame shift mutations as a novel mechanism for the generation of neutralization resistant mutants of human respiratory syncytial virus.

Authors:  B García-Barreno; A Portela; T Delgado; J A López; J A Melero
Journal:  EMBO J       Date:  1990-12       Impact factor: 11.598

10.  Association of a new type of cytopathogenic myxovirus with infantile croup.

Authors:  R M CHANOCK
Journal:  J Exp Med       Date:  1956-10-01       Impact factor: 14.307

View more
  26 in total

1.  Competition between the Sendai virus N mRNA start site and the genome 3'-end promoter for viral RNA polymerase.

Authors:  Philippe Le Mercier; Dominique Garcin; Eduardo Garcia; Daniel Kolakofsky
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

Review 2.  New generation live vaccines against human respiratory syncytial virus designed by reverse genetics.

Authors:  Peter L Collins; Brian R Murphy
Journal:  Proc Am Thorac Soc       Date:  2005

3.  Identification of human parainfluenza virus type 2 (HPIV-2) V protein amino acid residues that reduce binding of V to MDA5 and attenuate HPIV-2 replication in nonhuman primates.

Authors:  Anne Schaap-Nutt; Caraline Higgins; Emerito Amaro-Carambot; Sheila M Nolan; Christopher D'Angelo; Brian R Murphy; Peter L Collins; Alexander C Schmidt
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

Review 4.  Interplay between innate immunity and negative-strand RNA viruses: towards a rational model.

Authors:  Denis Gerlier; Douglas S Lyles
Journal:  Microbiol Mol Biol Rev       Date:  2011-09       Impact factor: 11.056

Review 5.  Progress in the development of human parainfluenza virus vaccines.

Authors:  Alexander C Schmidt; Anne Schaap-Nutt; Emmalene J Bartlett; Henrick Schomacker; Jim Boonyaratanakornkit; Ruth A Karron; Peter L Collins
Journal:  Expert Rev Respir Med       Date:  2011-08       Impact factor: 3.772

6.  Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

7.  Growth restriction of an experimental live attenuated human parainfluenza virus type 2 vaccine in human ciliated airway epithelium in vitro parallels attenuation in African green monkeys.

Authors:  Anne Schaap-Nutt; Margaret A Scull; Alexander C Schmidt; Brian R Murphy; Raymond J Pickles
Journal:  Vaccine       Date:  2010-02-20       Impact factor: 3.641

8.  The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness.

Authors:  Mario H Skiadopoulos; Stéphane Biacchesi; Ursula J Buchholz; Jeffrey M Riggs; Sonja R Surman; Emerito Amaro-Carambot; Josephine M McAuliffe; William R Elkins; Marisa St Claire; Peter L Collins; Brian R Murphy
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

9.  The marburg virus 3' noncoding region structurally and functionally differs from that of ebola virus.

Authors:  Sven Enterlein; Kristina M Schmidt; Michael Schümann; Dominik Conrad; Verena Krähling; Judith Olejnik; Elke Mühlberger
Journal:  J Virol       Date:  2009-02-18       Impact factor: 5.103

10.  Human parainfluenza virus type 2 V protein inhibits interferon production and signaling and is required for replication in non-human primates.

Authors:  Anne Schaap-Nutt; Christopher D'Angelo; Margaret A Scull; Emerito Amaro-Carambot; Machiko Nishio; Raymond J Pickles; Peter L Collins; Brian R Murphy; Alexander C Schmidt
Journal:  Virology       Date:  2009-12-07       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.